Novartis gets FDA approval for expanded use of Tasigna

06/17/2010 | Wall Street Journal, The

The FDA authorized Novartis to promote Tasigna as a treatment for adults in earlier stages of Philadelphia chromosome-positive chronic myeloid leukemia. The drug was approved in October 2007 for patients whose disease had progressed or who failed to respond to other treatments, including Novartis' Gleevec.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA